CLINICAL TRIAL • SUCCESSFUL PHASE I RESULTS

Phase IA and IB safety studies

• 30 total patients treated in Phase IA and IB trials
• Phase IA 400µg/day & Phase IB 800µg/day ]
• 3 control, 12 treated in each study phase
• No significant adverse effects
• Adverse events were mild and reported in both control and treatment groups
• All subjects completed the study

Open-label pilot study in Alzheimer’s patients

• 26 patients
• Conducted by Alan M. Mazurek, M.D., Neurologist, Rockville Center, NY
• 50µg -100µg (bid)
• No significant adverse effects reported
• Improvement in MMSE scores noted at 1,2 and 3 months
• Huperzine A observed to be safe, well-tolerated and effective